As a Corporate partner in the Bird & Bird Life Sciences team in Paris, I mainly advise innovative companies financed by venture capital, in particular biotech/medtech, digital health, and wellness companies.
I represent companies in the Life Sciences sector (biotech/medtech/healthtech), innovative technology companies and their executive, industrial or financial shareholders throughout their development: from incorporation, to venture capital and development capital fundraising operations, stock market financing, mergers and acquisitions and build-ups, as well as the structuring of joint ventures. I also represent French and foreign venture capital funds and corporate venture funds in the Life Sciences sector.
My goal is to create long-term relationships with my clients to assist them on their day-to-day business, but also on complex transactions, for their trade sale, their build up operations or for their IPO on Euronext or on other markets. I also represent French or foreign venture capital firms in connection with their investments in these life sciences companies.
I enjoy working with a genuine team of experts of the life sciences international team within Bird & Bird that can bring value to my clients, in particular in intellectual property, regulatory, IT, collaboration and licensing matters. I really feel that my corporate work for clients is enhanced by Bird & Bird's thorough knowledge of the life sciences industry in France and internationally.
For more than 10 years, I have been navigating the French life sciences ecosystem, with serial entrepreneurs, researchers, scientists, engineers and financiers, which is a fascinating world facing huge challenges for patients' health, including the revolution of artificial intelligence, data use and the digitalisation of health. I feel, in all humility, that I am contributing to this noteworthy and exciting cause: helping fund health research.
I am co-managing partner of the Bird & Bird offices in France since September 2021.